Emory Winship Cancer Institute

Site:	Emory Winship Cancer Institute	Go to their website
Address:	1365C Clifton Road
City:	Atlanta
State:	GA
Zip:	30322
Country:	USA

13 trials at this site

Phase	Trial	Trial Status	Site Status	Drug	NCT#
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Terminated	Active	Masitinib, (AB1010)	NCT00812240
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
1	A Phase I Trial of Bortezomib and Sunitinib	Ongoing, but not recruiting	Closed	Bortezomib + Sunitinib	NCT00720148
1	A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors	Ongoing, but not recruiting	Closed	SF1126	NCT00907205
1	Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies	Ongoing, but not recruiting	Closed	XL228	NCT00526838
1	Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma	Ongoing, but not recruiting	Closed	ARQ 092	NCT01473095
2	A Phase II Study of IMC-A12 in Children With Relapsed/Refractory Solid Tumors	Does not allow GIST	Active	IMC-A12	NCT00831844
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Completed	Closed	INBRX-109 + Temozolomide	NCT03715933
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915